Search

Your search keyword '"Rafei, Hind"' showing total 238 results

Search Constraints

Start Over You searched for: Author "Rafei, Hind" Remove constraint Author: "Rafei, Hind"
238 results on '"Rafei, Hind"'

Search Results

1. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

3. List of Contributors

4. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD

6. Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

7. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape

9. Contributors

10. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML.

11. Landscape of Immunotherapy in Genitourinary Malignancies

12. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles

15. Mitigating infection risks: The promise and challenge of bispecific antibodies in haematological malignancies.

17. Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial.

21. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering

24. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+B cell tumors: a phase 1/2 trial

26. Next‐generation chimeric antigen receptors for T‐ and natural killer‐cell therapies against cancer.

28. Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia

31. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

32. DAP10 Co-Stimulation Imparts Memory-like Features to CD5 Targeting Cord Blood Derived CAR-NK Cells

33. Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies

34. Generation and Screening of Various CD70 CAR NK Cells Identify the Most Effective Construct Against Hematologic Malignancies

35. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

36. Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells

38. CD70 CAR NK Cells in the Treatment of Multiple Myeloma

39. NK Cell Dysfunction in CLL Is Mediated through SHP-1 Signaling and Is Associated with Poor Prognosis

40. Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

41. Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

42. Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse

43. A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab

44. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

45. CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

46. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation

49. Lower Risk of Graft Versus Host Disease after Exposure to Checkpoint Inhibitors with the Use of Post-Transplant Cyclophosphamide Prophylaxis

50. AML-314: Post-Transplant Cyclophosphamide Reduces the Incidence of Acute Graft Versus Host Disease in AML/MDS Patients Who Receive Checkpoint Inhibitors After Allogeneic Stem Cell Transplant

Catalog

Books, media, physical & digital resources